JPRN-jRCTs031210134已完成未知
Safety and pharmacokinetic study of a new PET probe [18F]FEDAC in healthy adults
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 65age old（—）
- 性别
- Male
入选标准
- •1. Healthy male subjects aged 20 or older and under 65 at the time of informed consent
- •2. Subjects who provide written informed consent
- •3. Subjects with BMI of less than 25
排除标准
- •1. Subjects who have severe or progressive complications.
- •2. Subjects who have obvious abnormalities in physical and laboratory examinations after obtaining the informed consent
- •3. Subjects who have past history of severe drug hypersensitivity
- •4. Subjects with drug or alcohol addiction
- •5. Subjects who smoke
- •6. Subjects who have received medication or used vitamins, herbal medicines, or supplements within 14 days prior to their visit
- •7. Subjects who are claustrophobic
- •8. Subjects who have undergone an examination with radiation exposure for the purpose of medical treatment (X-ray, CT, PET, DEXA, etc.) within the past 12 months, or for the purpose of research within the past 6 months. Chest X-rays conducted as part of the annual medical check are excluded.
- •9. Subjects who are considered to be inappropriate to participate in this study.
研究者
相似试验
招募中
2 期
First in patients of a New PET Probe FEDACMalignant tumors(solid tumors)JPRN-jRCTs031220192Tamura Kentaro30
进行中（未招募）
不适用
A Phase 1B Study of the Safety and Pharmacokinetics of Ritonavir-Boosted Elvitegravir (GS-9137/r) Plus a Background Regimen (BR) in HIV-1 Infected, Antiretroviral Treatment-Experienced AdolescentsEUCTR2008-003917-29-GBGilead Sciences Incorporated24
进行中（未招募）
1 期
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.EUCTR2018-001516-30-BGGUERBET60
进行中（未招募）
1 期
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance ImagingMedDRA version: 22.1Level: LLTClassification code 10029817Term: Nuclear magnetic resonance imaging brainSystem Organ Class: 100000004848MedDRA version: 22.1Level: LLTClassification code 10072232Term: Nuclear magnetic resonance imaging spinalSystem Organ Class: 100000004848EUCTR2018-001516-30-PLGUERBET80
进行中（未招募）
1 期
Study to evaluate product flow, breakdown and elimination from the body of a new contrast agent used in radiological examination and to evaluate its safety and efficacy in children from 2 to 17 years.EUCTR2018-001516-30-SKGUERBET80